相似文献
1
Extracts from "clinical evidence": age related macular degeneration.
BMJ. 2000 Sep 23;321(7263):741-4. doi: 10.1136/bmj.321.7263.741.
2
Age related macular degeneration.
Clin Evid. 2005 Jun(13):762-75.
3
Age related macular degeneration.
Clin Evid. 2004 Jun(11):819-34.
4
Age related macular degeneration.
Clin Evid. 2003 Dec(10):727-43.
5
Treatment of subfoveal choroidal neovascularisation in age related macular degeneration: focus on clinical application of verteporfin photodynamic therapy.
Br J Ophthalmol. 2001 Apr;85(4):483-95. doi: 10.1136/bjo.85.4.483.
6
Age related macular degeneration.
Clin Evid. 2006 Jun(15):877-88.
7
[New therapeutic aspects in age-related macular degeneration].
Med Clin (Barc). 2007 Nov 10;129(17):658-9. doi: 10.1157/13112103.
8
[Past, present, and future therapeutically options in age related macular degeneration].
Oftalmologia. 2002;53(2):5-8.
9
Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.
Arch Ophthalmol. 1999 Oct;117(10):1329-45.
10
Combination therapy with verteporfin and anti-VEGF agents in neovascular age-related macular degeneration: where do we stand?
Br J Ophthalmol. 2010 Feb;94(2):143-5. doi: 10.1136/bjo.2009.159863.
引用本文的文献
1
Transforming growth factor-beta inhibition reduces progression of early choroidal neovascularization lesions in rats: P17 and P144 peptides.
PLoS One. 2013 May 31;8(5):e65434. doi: 10.1371/journal.pone.0065434. Print 2013.
2
Genetic basis of inherited macular dystrophies and implications for stem cell therapy.
Stem Cells. 2009 Nov;27(11):2833-45. doi: 10.1002/stem.159.
3
Burden of illness, visual impairment and health resource utilisation of patients with neovascular age-related macular degeneration: results from the UK cohort of a five-country cross-sectional study.
Br J Ophthalmol. 2007 Oct;91(10):1303-7. doi: 10.1136/bjo.2007.116939. Epub 2007 May 15.
4
Dietary analysis and patterns of nutritional supplement use in normal and age-related macular disease affected subjects: a prospective cross-sectional study.
Nutr J. 2004 Sep 28;3:16. doi: 10.1186/1475-2891-3-16.
5
Photodynamic therapy with verteporfin is effective, but how big is its effect? Results of a systematic review.
Br J Ophthalmol. 2004 Feb;88(2):212-7. doi: 10.1136/bjo.2003.019471.
6
A randomised controlled trial investigating the effect of nutritional supplementation on visual function in normal, and age-related macular disease affected eyes: design and methodology [ISRCTN78467674].
Nutr J. 2003 Oct 10;2:12. doi: 10.1186/1475-2891-2-12.
7
Age related macular degeneration.
BMJ. 2003 Mar 1;326(7387):485-8. doi: 10.1136/bmj.326.7387.485.
8
How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom?
Br J Ophthalmol. 2003 Mar;87(3):312-7. doi: 10.1136/bjo.87.3.312.
9
Cholesterol lowering drugs and risk of age related maculopathy: prospective cohort study with cumulative exposure measurement.
BMJ. 2003 Feb 1;326(7383):255-6. doi: 10.1136/bmj.326.7383.255.
本文引用的文献
1
Radiation-associated choroidal neovasculopathy.
Ophthalmology. 1999 Dec;106(12):2254-60. doi: 10.1016/S0161-6420(99)90524-9.
2
A prospective, randomized, double-masked trial on radiation therapy for neovascular age-related macular degeneration (RAD Study). Radiation Therapy for Age-related Macular Degeneration.
Ophthalmology. 1999 Dec;106(12):2239-47. doi: 10.1016/s0161-6420(99)90522-5.
3
Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.
Arch Ophthalmol. 1999 Oct;117(10):1329-45.
4
Randomized trial of radiation for age-related macular degeneration.
Am J Ophthalmol. 1999 May;127(5):574-8. doi: 10.1016/s0002-9394(99)00038-0.
5
Age-related macular degeneration and risk factors for the development of choroidal neovascularization in the fellow eye.
Curr Opin Ophthalmol. 1998 Jun;9(3):38-46. doi: 10.1097/00055735-199806000-00007.
6
Age-related macular degeneration: a review of experimental treatments.
Surv Ophthalmol. 1998 Sep-Oct;43(2):134-46. doi: 10.1016/s0039-6257(98)00014-9.
7
A randomized controlled clinical trial on the efficacy of radiation therapy in the control of subfoveal choroidal neovascularization in age-related macular degeneration: radiation versus observation.
Graefes Arch Clin Exp Ophthalmol. 1998 May;236(5):321-5. doi: 10.1007/s004170050085.
8
Tissue plasminogen activator-assisted surgical excision of subfoveal choroidal neovascularization in age-related macular degeneration: a randomized, double-masked trial.
Ophthalmology. 1997 Nov;104(11):1847-51; discussion 1852. doi: 10.1016/s0161-6420(97)30018-9.
9
Interferon alfa-2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration. Results of a prospective randomized placebo-controlled clinical trial. Pharmacological Therapy for Macular Degeneration Study Group.
Arch Ophthalmol. 1997 Jul;115(7):865-72. doi: 10.1001/archopht.1997.01100160035005.
10
Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. Macular Photocoagulation Study Group.
Arch Ophthalmol. 1997 Jun;115(6):741-7. doi: 10.1001/archopht.1997.01100150743009.
Zotero 插件